CHRISTINA DEFAMIO: Open Payments
NPI 1134428527 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$359 in 12 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $249 · 2025 $359
Food & beverage: $359
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $116 |
| Amgen Inc. | 1 | $73 |
| TG Therapeutics, Inc. | 2 | $42 |
| Biogen, Inc. | 2 | $41 |
| ABBVIE INC. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
Products named: UPLIZNA, BRIUMVI, LEQEMBI, UBRELVY, REXULTI, AUSTEDO XR, Ocrevus Zunovo.
Industry payments across PA — which companies pay providers there.
